Skip to Main Content

The Rockefeller University Hospital

Site Map Investigators Log-in
Search results for
  1. (MMA-0465) An Observational Study of Treated and Untreated Acute and Early HIV-1

  2. (MMA-0448) Viral and host factors in the transmission and pathogenesis of HIV

  3. (MMA-0559) The Role of the Gastrointestinal Lymphoid System in the Pathogenesis of HIV-1 Infection and Health

  4. (MMA-0591) HIV Elite Controller Study

  5. (MMA-0610) Randomized Trial of Open-Label Truvada with Atazanavir/ritonavir versus Multi-class Therapy

  6. (MMA-0613) A study of the safety, tolerability and pharmacokinetics of experimental drug KD-247

  7. (MMA-0643) Safety and Efficacy of Once Daily Raltegravir (MK-0518) versus Twice Daily Raltegravir, Each in Combination with TRUVADA™, in Treatment-Naïve HIV Infected Subjects

  8. (MMA-0705) A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of EVG/FTC/TDF/GS-9350 Vs Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

  9. (MMA-0606) Mucosal and Innate Immune Responses and Viral Reservoirs in Tissues and Cells During Acute HIV Infection, Version 4.0 (CHAVI-012)

  10. (MMA-0732) Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-7340 Monotherapy in Subjects with HIV-1 (GS-US-120-0104)

  11. (MMA-0728) A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy

  12. (MMA-0754) A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of Once-Daily Doses of Cenicriviroc or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients

  13. (MMA-0761) A Phase 3b Randomized, Open-Label Study in Virologically-Suppressed, HIV-1 Infected Patients (GS-US 236-0121)

  14. (MMA-0774) Immune Activation HIV Negative IDU

  15. (MMA-0776) Immune Activation HIV Positive IDU

  16. (MMA-0781) A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors

  17. (MMA-0774) Immune Activation HIV Negative IDU

  18. (MMA-0927) A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current INI-NNRTI-, or PI-based

  19. (MMA-0930) A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men a